O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate

We are O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate CAS:105832-38-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
CAS.NO:105832-38-0
Synonyms:N,N,N',N'-Tetramethyl-O-(N-succinimidyl)uronium Tetrafluoroborate;TSTU
Molecular Formula:C9H16BF4N3O3
Molecular Weight:301.04600
 
Physical and Chemical Properties:
Density:1.41;
Melting point:198-201oC;
 
HS Code: 2925190090
UN No.: UN1759
Hazard class: 8 categories 
Packing level: Class III
 
Specification:
Appearance:White crystal powder
Purity(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As a condensation reagent

O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate


Related News: Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage.21679-14-1 Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage.Methyl 6-bromopicolinate The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.N-(2-Pyrazinylcarbonyl)-L-phenylalanine The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.

Related Products
Product Name
2′,3′,5′-Tri-O-acetyl-D-adenosine View Details
2-(2-Chloroethoxy)-Benzenesulfonamide View Details
Dimethyl isopropylmalonate View Details
2,2,3,3,3-pentafluoropropanoyl Cas:356-42-3 manufacturer Furfuryl Mercaptan manufacturer D-Proline tert-Butyl Ester Hydrochloride manufacturer 4-Bromotoluene manufacturer Allyl chloride manufacturer